Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
2024年3月20日 - 8:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its fourth quarter and
full year 2023 financial results on Wednesday, March 27, 2024 and
will provide a business update.
Altimmune management will host a conference call
at 8:30 am E.T. on March 27 to discuss financial results and
provide a business update. The conference call will be webcast live
on Altimmune’s Investor Relations website at
https://ir.altimmune.com/investors.
Participants who would like to join the call may
register here to receive the dial-in numbers and unique PIN to
access the call. Shortly after the call, a replay will be available
on the Investor Relations website for up to three months.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation therapeutics for the treatment of obesity and liver
diseases. The Company’s lead product candidate, pemvidutide, is a
GLP-1/glucagon dual receptor agonist that is being developed for
the treatment of obesity and Metabolic Dysfunction-Associated
Steatohepatitis (MASH). In addition, Altimmune is developing
HepTcell™, an immunotherapeutic designed to achieve a functional
cure for chronic hepatitis B. For more information, please visit
www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor Contact:Richard
Eisenstadt Chief
Financial Officer
Phone:
240-654-1450 reisenstadt@altimmune.com
Media Contact:Danielle CanteyInizio Evoke
CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 4 2024 まで 5 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 5 2023 まで 5 2024